Research Reports Initiation on Medical Equipment Stocks -- Edwards Lifesciences, Hologic, and Stryker

Wednesday, May 3, 2017 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 3, 2017 /PRNewswire/ -- takes a closer look at these Medical Appliances and Equipment

stocks for today: Edwards Lifesciences Corp. (NYSE: EW), Hologic Inc. (NASDAQ: HOLX), and Stryker Corp. (NYSE: SYK). These companies operate in the Healthcare sector, which has received an "Outperform" rating from Charles Schwab
on April 27th, 2017 due to solid balance sheets, attractive dividend yields, an improved overall cost structure, and rising demand for sector products and services. Learn more about these stocks by downloading their free report at:

Edwards Lifesciences  

On Tuesday, shares in Irvine, California headquartered Edwards Lifesciences Corp. ended the session 0.19% higher at $110.11 with a total volume of 1.42 million shares traded. The Company's shares have gained 17.05% in the last one month, 14.41% over the previous three months, and 17.51% on an YTD basis. The stock is trading 15.56% above its 50-day moving average and 8.98% above its 200-day moving average. Moreover, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have a Relative Strength Index (RSI) of 83.68.

On April 26th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $114 a share to $118 a share.

On April 27th, 2017, Edwards Lifesciences announced that it is scheduled to present at the Deutsche Bank 42nd Annual Health Care Conference at The InterContinental Hotel in Boston, MA on Wednesday, May 03rd, 2017. Scott B. Ullem, CFO, is scheduled to speak to conference attendees at 10:40 a.m. ET. A live webcast of the presentation will be available on the Company's investor relations website. The free research report on EW is available at:


Marlborough, Massachusetts headquartered Hologic Inc.'s stock closed the day 0.13% lower at $45.30 with a total trading volume of 1.82 million shares. The Company's shares have advanced 6.46% in the past month, 11.77% in the previous three months, and 12.91% since the start of this year. The stock is trading 6.99% and 14.37% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 77.10.

On April 04th, 2017, Hologic announced that it plans to release its financial results for Q2 FY17 on Wednesday, May 10th, 2017, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. ET. The live webcast of the call may be accessed on the Company's website.

On April 04th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $46 a share to $50 a share. The complimentary report on HOLX can be downloaded at:


Kalamazoo, Michigan headquartered Stryker Corp.'s stock finished Tuesday's session 0.29% higher at $136.17. A total volume of 1.27 million shares was traded, which was above their three months average volume of 1.10 million shares. The Company's shares have advanced 3.43% in the last one month, 10.59% over the previous three months, and 14.02% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.83% and 13.67%, respectively. Additionally, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 70.15.

On April 25th, 2017, Stryker reported operating results for Q1 2017. Net sales grew 18.4% to $2.96 billion; reported net earnings per diluted share increased 9.3% to $1.17; and adjusted net earnings per diluted share increased 19.4% to $1.48. In addition, consolidated net sales of $2.96 billion increased 18.4% in the quarter, as reported, and 18.8% in constant currency. 

On April 26th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $135 a share to $140 a share. Get free access to your technical report on SYK at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store